• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Traditional Chinese Herbs Not Effective for Intracerebral Hemorrhage: A Randomized Trial

February 6, 2025

Herbs have been used in traditional Chinese medicine for centuries, but the effectiveness of many of these treatments remain unknown. Recently, various traditional medicines have been tested in randomized clinical trials with variable results. The Chinese herbal medicine in patients with acute intracerebral haemorrhage (CHAIN) trial was a double-blind, prospective, randomized study conducted at 26 hospitals in China. The CHAIN trial randomized 1,648 adult patients with spontaneous intracerebral hemorrhage (mean age, 67 years; 34% female; 84% bleeding at basal ganglia or thalamus) to receive either FYTF-919 (Zhongfeng Xingnao, a blend of four herbs) or a placebo (soybean peptide with black sugar syrup) orally every eight hours or via a nasogastric tube every six hours for 28 days. No differences were observed between study arms based on the utility weighted modified Rankin Scale at 90 days after randomization, which was 0.44 for both arms (mean difference, 0.01; 95% C.I., -0.02 to 0.04; p=0.63).  Furthermore, no differences were found in secondary outcomes, including death, disability, or health-related quality of life.  Although FYTF-919 was not effective, no adverse reactions occurred. Further randomized clinical trials are needed to evaluate other traditional Chinese medicines.

Reference:

Guo J, Chen X, Wu M, Wang D, et al. Traditional Chinese medicine FYTF-919 (Zhongfeng Xingnao oral prescription) for the treatment of acute intracerebral haemorrhage: a multicentre, randomised, placebo-controlled, double-blind, clinical trial.  The Lancet 2025; 404 (10468): 2187 – 2196.

Filed Under

  • News
  • Special Transfusion Situations

Recommended

  • First Autologous Human Transfusion of Engineered Platelets

  • Transfusion Guidelines for Major Hemorrhage

  • Plasma Transfusions in the United States

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Directed Blood Donations Should be Limited

  • Babesia Infection Reduces Red Cell Deformability

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley